Advertisement

Estrogens and Schizophrenia

  • Anita Riecher-Rössler

Keywords

Menstrual Cycle Biol Psychiatry Estrogen Deficiency Menstrual Irregularity Gonadal Dysfunction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahokas AJ, Turtiainen S, Aito M (1998) Sublingual oestrogen treatment of postnatal depression. Lancet 351: 109PubMedCrossRefGoogle Scholar
  2. Ahokas A, Aito M, Turtiainen S (2000) Association between oestradiol and puerperal psychosis. Acta Psychiatr Scand 101: 167–170PubMedCrossRefGoogle Scholar
  3. Barrett-Connor E, Stuenkel CA (2001) Hormone replacement therapy (HRT): risks and benefits. Int J Epidemiol 30: 423–426PubMedCrossRefGoogle Scholar
  4. Bédard P, Boucher R, Daigle M, Di Paolo T (1984) Similar effect of estradiol and haloperidol on experimental tardive dyskinesia in monkeys. Psychoendocrinology 9: 375–379Google Scholar
  5. Bergemann N, Mundt Ch, Resch F, Parzer P, Nagl I, Eller A, Runnebaum B (1996) On the hypoestrogen hypothesis in female schizophrenia: Preliminary results. Schizophr Res 18: 158CrossRefGoogle Scholar
  6. Bergemann N, Parzer P, Nagl I, Salbach B, Runnebaum B, Mundt Ch, Resch F (2002) Acute psychiatric admission and menstrual cycle phase in women with schizophrenia. Arch Women Ment Health 5:119–126PubMedGoogle Scholar
  7. Bleuler M (1943) Die spätschizophrenen Krankheitsbilder. Neurol XV 9: 259–290Google Scholar
  8. Braendle W, Breckwoldt M, Kuhl H, Riecher-Rössler A, Rohde A, Rüther E (2001) Sexualhormone und Psyche — Ergebnisse des 2. Interdisziplinären Frankfurter Gesprächs zur Kontrazeption. Frauenarzt 42: 154–160Google Scholar
  9. Canuso CM, Goldstein JM, Wojcik J, Dawson R, Brandman D, Klibanski A, Schildkraut JJ, Green AI (2002) Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res 111: 11–20PubMedCrossRefGoogle Scholar
  10. Carter DA, McGarrick GM, Norton KRW, Paykel ES, Prysor-Jones RA, Whitehead SA (1982) The effect of chronic neuroleptic treatment on gonadotrophin release. Psychoneuroendocrinology 7: 201–207PubMedCrossRefGoogle Scholar
  11. Chang SS, Renshaw DC (1986) Psychosis and pregnancy. Compr Ther 12: 36–41PubMedGoogle Scholar
  12. Choi SH, Kang SB, Joe SH (2001) Changes in premenstrual symptoms in women with schizophrenia: a prospective study. Psychosom Med 6: 822–829Google Scholar
  13. Cohen RZ, Seeman MV, Gotowiec A, Kopala L (1999) Earlier puberty as a predictor of later onset of schizophrenia in women. Am J Psychiatry 156: 1059–1064PubMedGoogle Scholar
  14. Cyr M, Calon F, Morissette M, Di Paolo T (2002) Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson’s disease. J Psychiatry Neurosci 27: 12–27PubMedGoogle Scholar
  15. Davis SR (2002) The effects of tibolone on mood and libido. Menopause 9: 162–170PubMedGoogle Scholar
  16. De Battista C, Lawrence Smith D, Schatzberg AF (1999) Modulation of monoamine neurotransmitters by estrogen: clinical implications. Rev Psychiatry 18: 137–166Google Scholar
  17. de Noaves Soares C, Almeida OP, Joffe H, Cohen LS (2001) Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women. Arch Gen Psychiatry 58: 529–534Google Scholar
  18. Diczfalusy E, Lauritzen C (1961) Psychiatrische und neurologische Erkrankungen. In: Diczfalusy E, Lauritzen C (eds) Östrogene beim Menschen. Springer, Berlin Heidelberg, pp 461–462Google Scholar
  19. DiPaolo T, Payet P, Labrie F (1981) Effect of chronic estradiol and haloperidol treatment on striatal dopamine receptors. Eur J Pharmacol 73: 105–106Google Scholar
  20. Endo M, Daiguji M, Asano Y, Yamashita I, Takahashi S (1978) Periodic psychosis recurring in association with menstrual cycle. J Clin Psychiatry 39: 456–466PubMedGoogle Scholar
  21. Fink G, Sumner BEH (1996) Oestrogen and mental state. Nature 383: 306PubMedCrossRefGoogle Scholar
  22. Fink G, Sumner BEH, Rosie R, Grace O, Quinn JP (1996) Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol 16: 325–344PubMedCrossRefGoogle Scholar
  23. Garcia-Segura LM, Azcoitia I, Don Carlos LL (2001) Neuroprotection by estradiol. Progr Neurobiol 63: 29–60PubMedCrossRefGoogle Scholar
  24. Gattaz WF, Behrens S, De Vry J, Häfner H (1992) Östradiol hemmt Dopaminvermittelte Verhaltensweisen bei Ratten: Ein Tiermodell zur Untersuchung der geschlechtsspezifischen Unterschiede bei der Schizophrenie. Fortschr Neurol Psychiatrie 1: 1–44Google Scholar
  25. Gattaz WF, Vogel P, Riecher-Rössler A, Soddu G (1994) Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biol Psychiatry 36: 137–139PubMedCrossRefGoogle Scholar
  26. Gerada C, Reveley A (1988) Schizophreniform psychosis associated with the menstrual cycle. Br J Psychiatry 152: 700–702PubMedGoogle Scholar
  27. Glick J, Stewart D (1980) A new drug treatment for premenstrual exacerbation of schizophrenia. Compr Psychiatry 21: 281–287PubMedCrossRefGoogle Scholar
  28. Gordon JH, Borison RL, Diamond BL (1980) Modulation of dopamine receptors sensitivity by estrogen. Biol Psychiatry 15: 389–396PubMedGoogle Scholar
  29. Gordon JH, Diamond BI (1981) Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia. Biol Psychiatry 16: 365–371PubMedGoogle Scholar
  30. Gregoire AJP, Kumar R, Everitt B, Henderson AF, Studd JWW (1996) Transdermal oestrogen treatment of severe postnatal depression. Lancet 347: 930–933PubMedCrossRefGoogle Scholar
  31. Grigoriadis S, Seeman MV (2002) The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can J Psychiatry 47: 437–442PubMedGoogle Scholar
  32. Häfner H, Riecher-Rössler A, Hambrecht M, Maurer K, Meissner S, Schmidtke A, Fätkenheuer B, Löffler W, an der Heiden W (1991a) Geschlechtsunterschiede bei schizophrenen Erkrankungen. Fortschr Neurol Psychiatrie 59: 343–360Google Scholar
  33. Häfner H, Behrens S, De Vry J, Gattaz WF, Löffler W, Maurer K, Riecher-Rössler A (1991b) Warum erkranken Frauen später an Schizophrenie? Erhöhung der Vulnerabilitätsschwelle durch Östrogen. Nervenheilkunde 10: 154–163Google Scholar
  34. Häfner H, Behrens S, De Vry J, Gattaz WF (1991c) An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia. Psychiatry Res 38: 125–143PubMedGoogle Scholar
  35. Halbreich U (2002) The spectrum of estrogens, estrogen agonists and SERMS — abstract. Int J Neuropsychopharmacol 5(Suppl 1): S12Google Scholar
  36. Hallonquist JD, Seeman MV, Lang M, Rector NA (1993) Variation in symptom severity over the menstrual cycle of schizophrenics. Biol Psychiatry 33: 207–209PubMedCrossRefGoogle Scholar
  37. Hoff AL, Kremen WS, Wieneke MH, Lauriello J, Blankfeld HM, Faustman WO, Csemansky JG, Nordahl TE (2001) Association of estrogen levels with neuropsychological performance in women with schizophrenia. Am J Psychiatry 158: 1134–1139PubMedCrossRefGoogle Scholar
  38. Holsboer F (1983) Hormones. In: Hippius H, Winokur G (eds) Psychopharmacology 1. Excerpta Medica, Amsterdam Oxford Princeton, 144–161Google Scholar
  39. Honigfeld G, Gillis RD, Klett CJ (1976) NOSIE: Nurses' observation scale for inpatient evaluation. In: Guy W (ed) ECDEU Assessment Manual for Psychopharmocology. Rockville MD, NIMHGoogle Scholar
  40. Hruska RE, Silbergeld EK (1980) Estrogen treatment enhances dopamine receptor sensitivity in the rat striatum. Eur J Pharmacol 61: 397–400PubMedCrossRefGoogle Scholar
  41. Huber TJ (2001) Hormonspiegel bei Frauen mit psychotischen Erkrankungen. In: Riecher-Rössler A, Rohde A (eds) Psychische Erkrankungen bei Frauen — für eine geschlechtersensible Psychiatrie und Psychotherapie. Karger, Basel Freiburg Paris London New York New Delhi Bangkok Singapore Tokyo Sidney, 165–169Google Scholar
  42. Huber TJ, Rollnik J, Wilhelms J, von zur Mühlen A, Emrich HM, Schneider U (2001) Estradiol levels in psychotic disorders. Psychoneuroendocrinology 26: 27–35PubMedCrossRefGoogle Scholar
  43. Hutchinson G, Bhugra D, Mallett R, Burnett R, Corridan B, Leff J (1999) Fertility and marital rates in first-onset schizophrenia. Soc Psychiatry Psychiatr Epidemiol 34: 617–621PubMedCrossRefGoogle Scholar
  44. Jeste DV, Lindamer LA, Lacro JP (2001) Gender differences in late-life schizophrenia and its treatment — abstract. Syllabus and Proc Summary of the American Psychiatric Association’s 2001 Annual Meeting, 310Google Scholar
  45. Kendell RE, Chalmers JC, Platz C (1987) Epidemiology of puerperal psychoses. Br J Psychiatry 150: 662–673PubMedGoogle Scholar
  46. Klaiber EL, Broverman DM, Vogel U, Kobayashi Y (1979) Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry 36: 550–554PubMedGoogle Scholar
  47. Koller WC, Weiner WJ, Klawans HL, Nausieda PA (1980) Influence of female sex hormones on neuroleptic-induced behavioral supersensitivity. Neuropharmacol 19: 387–391Google Scholar
  48. Kraepelin E (1909) Psychiatrie, vol. 1–4, 8th ed. Barth, LeipzigGoogle Scholar
  49. Krafft-Ebing G (1896) Untersuchungen über Irresein zur Zeit der Menstruation: Ein klinischer Beitrag zur Lehre vom periodischen Irresein. Arch Psychiatry 8: 65–107Google Scholar
  50. Kretschmer E (1921) Körperbau und Charakter. Untersuchungen zum Konstitutionsproblem und zur Lehre von den Temperamenten, 25th ed. Springer, BerlinGoogle Scholar
  51. Kuhl H (2002) Einfluss von Östrogenen und Gestagenen auf das Zentralnervensystem. In: Kuhl H (ed) Sexualhormone und Psyche. Thieme, Stuttgart, 9–17Google Scholar
  52. Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D (1996) A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 20: 247–252PubMedCrossRefGoogle Scholar
  53. Kulkarni J, Riedel A, de Castella AR et al. (2001) Estrogen — a potential treatment for schizophrenia. Schizophr Res 48: 137–144PubMedCrossRefGoogle Scholar
  54. Labhart A (1978) Klinik der inneren Sekretion. Springer, Berlin Heidelberg New YorkGoogle Scholar
  55. Lindamer LA, Lohr JB, Harris MJ et al. (1997) Gender, estrogen, and schizophrenia. Psychopharmacol Bull 33: 221–228PubMedGoogle Scholar
  56. Lindamer LA, Buse DC, Lohr JB, Jeste DV (2001) Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol Psychiatry 49: 47–51PubMedCrossRefGoogle Scholar
  57. Maguire GA (2002) Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 63(Suppl 4): 56–62PubMedGoogle Scholar
  58. Mahé V, Dumaine A (2001) Oestrogen withdrawal associated psychoses. Acta Psychiatr Scand 104: 323–331PubMedGoogle Scholar
  59. Mall G (1959) Neuere Ergebnisse der Psycho-Endokrinologie. Ärztliche Praxis XI: 1357–1360Google Scholar
  60. Mall G (1960) Diagnostik und Therapie ovarieller Psychosen. Zentralblatt Gesamte Neurol Psychiatrie 155: 250Google Scholar
  61. McEwen BS, Alves SE, Bulloch K, Weiland NG (1998) Clinically relevant basic science studies of gender differences and sex hormone effects. Psychopharmacol Bull 34: 251–259PubMedGoogle Scholar
  62. NAMS (2000) A decision tree for the use of estrogen replacement therapy or hormone replacement therapy in postmenopausal women: consensus opinion of the North American Menopause Society. Menopause 7: 76–86Google Scholar
  63. Neumann NU, Frasch K (2001) Olanzapin und Schwangerschaft — zwei Kasuistiken. Nervenarzt 72: 876–878PubMedCrossRefGoogle Scholar
  64. Nicoletti F, Ferrara N, Patti F, Viglianesi M, Rampello L, Bianchi A, Reggio A, Scapagnini U (1983) Influence of sex steroids and prolactin on haloperidol-induced catalepsy. Brain Res 279: 352–358PubMedCrossRefGoogle Scholar
  65. Oesterlund MK (2002) The role of estrogens in neuropsychiatric disorders. Curr Opin Psychiatry 15: 307–312Google Scholar
  66. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Report 10: 799–812Google Scholar
  67. Rasgon NL, Small GW, Siddarth P, Miller K, Ercoli LM, Bookheimer SY, Lavretsky H, Huang SC, Barrio JR, Phelps ME (2001) Estrogen use and brain metabolic change in older adults. A preliminary report. Psychiatry Research: Neuroimaging Section 107: 11–18Google Scholar
  68. Riecher A, Maurer K, Löffler W, Fätkenheuer B, an der Heiden W, Munk-Jørgensen P, Strömgren E, Häfner H (1990) Gender differences in age at onset and course of schizophrenic disorders. In: Häfner H, Gattaz WF (eds) Search for the causes of schizophrenia, vol. 2, 15–33Google Scholar
  69. Riecher-Rössler A, Häfner H (1993) Schizophrenia and oestrogens — is there an association? Euro Arch Psychiatry Clin Neurosci 242: 323–328Google Scholar
  70. Riecher-Rössler A (1994) Die Spätschizophrenie — eine valide Entität? Eine empirische Studie zu Risikofaktoren, Krankheitsbild und Verlauf. Habilitationsschrift, Universität Heidelberg-MannheimGoogle Scholar
  71. Riecher-Rössler A, Häfner H, Stumbaum M, Maurer K, Schmidt R (1994a) Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 20: 203–214PubMedGoogle Scholar
  72. Riecher-Rössler A, Häfner H, Dütsch-Strobel A, Oster M, Stumbaum M, van Gülick-Bailer M, Löffler W (1994b) Further evidence for a specific role of estradiol in schizophrenia? Biol Psychiatry 36: 492–494PubMedGoogle Scholar
  73. Riecher-Rössler A, Löffler W, Munk-Jørgensen P (1997) What do we really know about late-onset schizophrenia? Eur Arch Psychiatry Clin Neurosci 247: 195–208PubMedCrossRefGoogle Scholar
  74. Riecher-Rössler A, Häfner H, Dütsch-Strobel A, Stumbaum M (1998) Gonadal function and its influence on psychopathology. A comparison of schizophrenic and non-schizophrenic female inpatients. Arch Women Ment Health 1: 15–26Google Scholar
  75. Riecher-Rössler A (2002) Estrogen effects in schizophrenia and their potential the-rapeutic implications — review. Arch Women Ment Health 5: 111–118PubMedGoogle Scholar
  76. Riecher-Rössler A (2003) Estrogens and schizophrenia. Curr Opin Psychiatry 16: 187–192Google Scholar
  77. Ripley HS, Papanicolaou GN (1942) The menstrual cycle with vaginal smear studies in schizophrenia, depression and elation. Am J Psychiatry 98: 567–573Google Scholar
  78. Schepp A (1997) Pilotstudie zur Frage eines überdauernden relative Hypoöstrogenismus bei schizophrenen Frauen. Inauguraldissertation zur Erlangung des medizinischen Doktorgrades, Universität Heidelberg-MannheimGoogle Scholar
  79. Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, Murphy JH, Rubinow DR (2000) Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecology 183: 414–420Google Scholar
  80. Scriba PC, von Werder K (1976) Hypothalamus und Hypophyse. In: Siegenthaler W (ed) Klinische Pathophysiologie. Thieme, Stuttgart, pp 278–306Google Scholar
  81. Seeman MV (1983) Interaction of sex, age and neuroleptic dose. Compr Psychiatry 24: 125–128PubMedCrossRefGoogle Scholar
  82. Sichel DA, Cohen LS, Robertson LM et al. (1995) Prophylactic estrogen in recurrent postpartum affective disorders. Biol Psychiatry 38: 814–818PubMedCrossRefGoogle Scholar
  83. Smith S, Wheeler MJ, Murray R, O'Keane V (2002) The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 22: 109–114PubMedCrossRefGoogle Scholar
  84. Stahl SM (1998) Basic psychopharmacology of antidepressants, part 2: estrogen as an adjunct to antidepressant treatment. J Clin Psychiatry 59(Suppl 4): 15–24PubMedGoogle Scholar
  85. Stahl SM (2001a) Effects of estrogen on the central nervous system. J Clin Psychiatry 62: 317–318PubMedGoogle Scholar
  86. Stahl SM (2001b) Why drugs and hormones may interact in psychiatric disorders. J Clin Psychiatry 62: 225–226PubMedGoogle Scholar
  87. von Zerssen D, Koeller DM (1976) Klinische Selbstbeurteilungs-Skalen (KSb-Si) aus dem Münchener Psychiatrischen Informations-System (PSYCHIS München). Manual. Beltz, WeinheimGoogle Scholar
  88. Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288: 321–333Google Scholar
  89. Zhang-Wong J, Seeman MV (2002) Antipsychotic drugs, menstrual regularity, and osteoporosis risk. Arch Women Ment Health 5: 93–98PubMedGoogle Scholar
  90. Zweifel JE, O'Brien WH (1997) A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 22: 189–212PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2005

Authors and Affiliations

  • Anita Riecher-Rössler

There are no affiliations available

Personalised recommendations